Literature DB >> 19051498

Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.

K Ota1, S Kurita, M Nishimura, M Ogawa, Y Kamei, K Imai, Y Ariyoshi, K Kataoka, M Murakami, A Oyama, A Hoshino, H Amo, T Kato.   

Abstract

The combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside (MFC), which had a marked synergistic effect in the treatment of L1210 mouse leukemia, was used clinically against advanced cancer. Response was assessed according to criteria proposed by Karnofsky. Of 90 patients with various kinds of solid tumors, 17 (19%) had I-B responses and 20 (22%) had I-A responses. Either I-A or I-B responses were observed in 15 (55%) of 27 patients with cancer of the stomach and in nine (60%) of 15 patients with cancer of the colon, indicating that the MFC combination is especially effective against gastrointestinal adenocarcinoma. Bone marrow suppression and gastrointestinal toxicity were observed; however, if the MFC therapy is carried out carefully with adequate intervals between treatments and periodic blood tests, it can be expected to be a safe and useful treatment that is superior to other chemotherapy especially for gastrointestinal cancers.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 19051498

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  11 in total

1.  Treatment of gastric cancer, with special reference to the survivals of the cancer patients treated with multiple combination MFC therapy or immunochemotherapy of MFC plus OK-432 (NSC B116209).

Authors:  S Suga; H Tsunekawa; M Washino; N Makino; Z Tamura; S Goto
Journal:  Gastroenterol Jpn       Date:  1977

2.  Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma.

Authors:  S Koyama; A Ozaki; Y Iwasaki; T Sakita; T Osuga; A Watanabe; M Suzuki; T Kawasaki; T Soma; T Tabuchi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  The concept of immunochemosurgery in gastric cancer.

Authors:  J P Kim
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

4.  The chemotherapy of large-bowel cancer. Present status and future prospects.

Authors:  J Horton; C B Hacker; T J Cunningham; R W Sponzo
Journal:  Am J Dig Dis       Date:  1974-11

5.  Combination chemotherapy enhances survival of patients with unresectable gastric cancer.

Authors:  T Kano; Y Hiramoto; Y Abe; T Notsuka; H Masuda; R Tamada; R Kumashiro; K Inokuchi
Journal:  Jpn J Surg       Date:  1983-09

6.  Mitomycin C: experience in the United States, with emphasis on gastric cancer.

Authors:  P S Schein; J S Macdonald; D Hoth; P V Wooley
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach.

Authors:  T Kano; R Kumashiro; R Tamada; Y Kodama; K Inokuchi
Journal:  Jpn J Surg       Date:  1981

8.  A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Tokai cooperative study group for adjuvant chemoimmunotherapy of stomach cancer.

Authors:  M Yasue; M Murakami; H Nakazato; T Suchi; K Ota
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 9.  Review of adjuvant chemotherapy for gastric cancer.

Authors:  T Nakajima
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

10.  Ursodeoxycholic acid prevents gastrointestinal disorders caused by anticancer drugs.

Authors:  T Tatsumura; H Sato; K Yamamoto; T Ueyama
Journal:  Jpn J Surg       Date:  1981-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.